Last reviewed · How we verify
Apheresis donation
At a glance
| Generic name | Apheresis donation |
|---|---|
| Sponsor | Etablissement Français du Sang |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- The Effect of Plasma Donation Frequency on Donor Health (NA)
- Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany
- Stress Ball and Music to Reduce Anxiety and Pain in Platelet Apheresis (NA)
- Delayed Tolerance Through Mixed Chimerism (PHASE1, PHASE2)
- grouP O wholE blooD : storagE leSion impacT And infLammation (NA)
- Autologous Cold-stored Apheresis Platelets (PHASE2, PHASE3)
- Clinical Evaluation of the CM-1500 During Apheresis Blood Donation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apheresis donation CI brief — competitive landscape report
- Apheresis donation updates RSS · CI watch RSS
- Etablissement Français du Sang portfolio CI